Compare AbbVie Inc (ABBV) vs Valero Energy Corporation (VLO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Valero Energy Corporation — how do they compare? AbbVie Inc trades at $253.65 (market cap $449.91B), while Valero Energy Corporation trades at $277.96 (market cap $79.05B). The key difference: AbbVie Inc is far larger — about 5.7× Valero Energy Corporation's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | VLO | |
|---|---|---|
Market Cap | $449.91B | $79.05B |
Sector | Health | Energy |
52-Week High | $261.07 | $270.32 |
52-Week Low | $184.85 | $131.77 |
Enterprise Value | $513.38B | $84.81B |
Dividend Yield | 2.72% | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Valero Energy (VLO) trades at $266.22, down 0.58% on the day, with strong technical momentum showing bullish moving averages and key resistance at $270. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 expected at $10.08 EPS. Fundamentals show solid profitability with 17.72% ROE and attractive valuation metrics including P/E of 19.75 and P/S of 0.66. Recent news highlights VLO's refining strength and renewable fuels growth potential.
VLO presents a compelling investment case with strong analyst support (58% buy ratings) and a consensus price target of $258.25. The company's Gulf Coast refining advantage and clean-fuel initiatives support long-term growth, though investors face risks from energy market volatility and declining revenue trends from $176.4B in 2022 to $122.7B in 2025. The current price near resistance levels suggests potential for breakout or consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
